Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Eli Lilly’s revenue has soared in recent years thanks to its leadership in the weight loss drug market. Eli Lilly (NYSE: LLY) ...

Key Points Visa, Netflix and Eli Lilly are moving closer to the trillion dollar club. While all three have the potential, one ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing ...

Financial Stability: Eli Lilly's balance sheet is more robust, with debt making up only 4% of equity, considerably less than ...

Shares of Eli Lilly & Co. LLY rallied 4.33% to $807.19 Tuesday, on what proved to be an all-around positive trading session ...

LLY breaks above its 50-day average as Mounjaro and Zepbound drive revenues. Is this a new entry point for investors?

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...